Navigation Links
Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
Date:8/15/2011

ients with HIBM typically begin to have weakness and abnormal walking at 18 to 30 years of age. Over the ensuing 10 to 20 years, many patients progressively lose significant functional ability and become wheelchair-bound. There are no current treatments for HIBM.

UX001 is an extended release formulation of sialic acid that should allow the maintenance of steady levels of sialic acid after oral administration. The sialic acid replacement therapy is expected to restore the proper biochemistry of glycoproteins and glycolipids by allowing proper sialylation.  Data from an HIBM mouse model show a profound beneficial effect of sialic acid replacement therapy on the biochemistry, pathology and clinical outcomes of HIBM mice.

About Ultragenyx

Ultragenyx is a private, clinical-stage biotechnology company committed to developing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases. Ultragenyx is leveraging its experience in orphan indications to identify target diseases with well understood biological mechanisms to generate a pipeline of promising treatments for medically underserved patient populations. Ultragenyx' lead program, UX001, is currently being evaluated in a Phase 1 trial in hereditary inclusion body myopathy (HIBM).

Ultragenyx aspires to create a new model for successful rare disease drug development and to deliver significant value to all its key stakeholders by rapidly and efficiently transforming good science into great medicines for untreated rare diseases. Ultragenyx' investors include TPG Biotech and Fidelity Biosciences, HealthCap and Pappas Ventures. The company is led by Emil Kakkis, MD, PhD, a recognized industry leader in rare disease research and development.

For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.


'/>"/>
SOURCE Ultragenyx Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. American Regent, Inc. Initiates Voluntary Recall of Seventeen Lots of Vasopressin Injection, USP, Multiple Dose Vials due to Sub-Potency
2. Isis Initiates Phase 1 Study of ISIS-PTP1BRx to Treat Type 2 Diabetes
3. American Regent Initiates Voluntary Nationwide Recall of Calcium Gluconate Injection, USP, 10%, 100 mL Pharmacy Bulk Package Due to Particulates
4. EntreMed Enters into $7.5 Million Equity Facility and Initiates $1.1 Million Drawdown
5. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
6. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
7. Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression
8. Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™
9. American Regent Initiates Voluntary Nationwide Recall of Concentrated Sodium Chloride Injection, USP, 23.4%, 30 mL Single Dose Vial Due to Particulates
10. Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
11. Masimo Initiates Limited Market Release of E1, Single-Patient-Use Ear Sensor for Pulse Oximetry Monitoring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... NORTHFIELD, Ill., Aug. 22, 2011 The latest developments ... be featured topics when more than 1,000 pathologists gather ... for the annual scientific meeting of the College ... THE Pathologists, Meeting™ will highlight advances in digital ...
... SANTA ANA, Calif., Aug. 22, 2011 Abbott (NYSE: ... expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) ... The  clear, viscous, low molecular weight dispersive ... in cataract extraction, intraocular lens (IOL) implantation, corneal transplantation, ...
Cached Medicine Technology:Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens 2Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens 3Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery 2
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay News) ... is starting to spread faster than ever, the World Health Organization ... viral infection were reported in just one week. That brings ... half of those reported in the past three weeks, the ... WHO has estimated that as many as 20,000 people could ...
(Date:9/18/2014)... Los Angeles, CA (PRWEB) September 18, 2014 ... manufacture and refine carbon dioxide, selling it to ... The largest markets for carbon dioxide are food and ... freeze products, such as fruits, vegetables or pizzas. The ... additive. Beverage manufacturers use the compound to carbonate soft ...
(Date:9/18/2014)... exercise is good for you. But new research from ... an added benefit for cancer patients undergoing chemotherapy. , ... found that combining exercise with chemotherapy shrunk tumors more ... professor in the School of Nursing and director of ... the senior author on the study, which appears in ...
(Date:9/18/2014)... WA (PRWEB) September 18, 2014 Qualis ... organizations, has published a white paper, “Advancing Primary ... of Health Information Technology.” , Authors Jeff Hummel, ... CCE provide guidance to organizations engaged in the work ... how health IT can bolster PCMH objectives, such as ...
(Date:9/18/2014)... one-day conference at the Milken Institute School of Public ... 2014 to discuss the Global Health Security Agenda (GHSA) ... this event is to invite discussion of proposed priorities ... action plans to curtail the current deadly Ebola outbreak. ... organizations and more than 50 countries have engaged in ...
Breaking Medicine News(10 mins):Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2
... Webinar: , , What: Coverity Webinar, ... 10 am PT, Where:, http://seminar2.techonline.com/registration/distrib.cgi?s=1346&d=2794 , ... the web at the, ... , Overview: , In this web seminar, ...
... Vista, LLC, a marketing,and information services firm focusing on ... Kevin Grossman, who has been with the company,for seven ... , In his new role, ... HRmarketer Services Group. Mr. Grossman will continue,to report ...
... DiseasePHOENIX, Feb. 12 Although major advances have been ... attention needs to be given to one of the ... -- the painful and often progressive condition called lymphedema, ... so much about cardiovascular disease, few physicians are familiar ...
... Md., Feb. 11 Dialysis Corporation of America (Nasdaq: ... fourth quarter and full year 2008 financial results on Thursday, ... company will also host a conference call in conjunction with ... following morning, Friday, March 6, 2009 at 10:00 AM EST. ...
... Study suggest streamlining of prescribing system to avoid ... -- Doctors often override electronic medication safety alerts ... prescribing drugs for patients, which suggests that physicians ... a U.S. study. , Researchers looked at ...
... Corporation (Nasdaq: RGEN ), a global leader ... today that the Company has received ISO 9001:2000 (ISO) ... and quality systems. ISO certification was granted for ... and related services underlying its Protein A business. ...
Cached Medicine News:Health News:Webinar Alert: Coverity Announces Verification and Validation of Medical Device Software with Static Analysis - A Review of FDA Guidance and Best Practices 2Health News:Kevin Grossman Named President of HRmarketer.com 2Health News:Vascular Experts Call for Increased Awareness of Growing Problem of Lymphedema 2Health News:Vascular Experts Call for Increased Awareness of Growing Problem of Lymphedema 3Health News:Dialysis Corporation of America Announces Fiscal Year 2008 Earnings Release Date 2Health News:Docs Override Most Electronic Drug Warnings 2Health News:Repligen Announces ISO 9001:2000 Certification 2Health News:Repligen Announces ISO 9001:2000 Certification 3
... Flexible biopsy forceps are extremely delicate ... incompetent repair source, they can easily be ... turn, damage your endoscopes. , On the ... flexible biopsy forceps can have a virtually ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
... With our factory-quality repairs, physicians know ... why more hospitals turn to Mobile Instrument ... We offer a full line of carbide ... our four-way quality control process. You'll enjoy ...
Inquire...
Medicine Products: